Liminatus Pharma (NASDAQ:LIMN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Liminatus Pharma (NASDAQ:LIMN – Free Report) to a hold rating in a research report released on Saturday morning.

Liminatus Pharma Price Performance

LIMN opened at $6.33 on Friday. Liminatus Pharma has a 52-week low of $4.40 and a 52-week high of $33.66.

About Liminatus Pharma

(Get Free Report)

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Recommended Stories

• Five stocks we like better than Liminatus Pharma
• Stock Average Calculator
• These 3 Undervalued Stocks Could Surge as Value Rotation Nears
• How to Know Which Cryptocurrency to Buy: A Guide for Investors
• Tilray Shares Blazing: What’s Behind the 55% Rally This Month?
• Comparing and Trading High PE Ratio Stocks
• 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up